PYC Therapeutics Ltd. is a drug-development company, which provides a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The firm's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.
Follow-Up Questions
Who is the CEO of PYC Therapeutics Ltd?
Dr. Rohan Hockings is the Chief Executive Officer of PYC Therapeutics Ltd, joining the firm since 2016.
What is the price performance of PYCXF stock?
The current price of PYCXF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for PYC Therapeutics Ltd?
PYC Therapeutics Ltd belongs to Biotechnology industry and the sector is Health Care
What is PYC Therapeutics Ltd market cap?
PYC Therapeutics Ltd's current market cap is $0
Is PYC Therapeutics Ltd a buy, sell, or hold?
According to wall street analysts, 7 analysts have made analyst ratings for PYC Therapeutics Ltd, including 1 strong buy, 8 buy, 1 hold, 0 sell, and 1 strong sell
